Nardev S. Khurmi - Concepedia

Author

Nardev S. Khurmi

Also Known As

N S Khurmi, N. S. KHURMI, N. S. Khurmi, N.S. Khurmi, Nardev Khurmi, Nardev S Khurmi, Nardev S. Khurmi, Nardev Singh Khurmi

Publications

4.4K

Citations

H-Index

Concepts

All Affiliations

Northwick Park Hospital AstraZeneca (United States)Clinical Research Institute Brigham and Women's Hospital University of Glasgow

About

Nardev S. Khurmi is an author at Northwick Park Hospital specializing in medicine, cardiovascular disease, and cardiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	24	1.7K
2	Health Sciences	5	5	94
3	Public Health	4	4	1.1K
4	Applied Physiology	4	4	66
5	Emergency Medicine	4	4	942

Nardev S. Khurmi

Publications

Citations

H-Index

Page 1

	Year	Citations
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes Hertzel C. Gerstein, Naveed Sattar, Julio Rosenstock, New England Journal of Medicine	2021	719
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study Christopher P. Cannon, Robert A. Harrington, Stefan James, The Lancet ThrombosisRandomised Double-blind StudyCardiovascular DiseaseMedicineCoronary Artery Disease	2010	658
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes Robert F. Storey, Richard C. Becker, Robert A. Harrington, European Heart Journal Dyspnoea AePharmacotherapyCoronary Artery DiseasePlatelet InhibitionAcute Myocardial Infarction	2011	200
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack Stefan James, Robert F. Storey, Nardev S. Khurmi, Circulation	2012	131
Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein Paul M. Ridker, Francisco Antônio Helfenstein Fonseca, Jacques Genest, The American Journal of Cardiology Jupiter TrialPreventive MedicineHealth PolicyCardiovascular DiseaseClinical Trials	2007	125
Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial Carolyn S.P. Lam, Chinthanie Ramasundarahettige, Kelley R. Branch, Circulation	2021	119
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial Rury R. Holman, Mary Angelyn Bethel, Jyothis T. George, American Heart Journal Non-pharmacological InterventionCardiovascular DiseaseHealth PolicyAntihypertensive TherapyClinical Trials	2015	103
Randomized double-blind comparison of verapamil and nifedipine in chronic stable angina V. Bala Subramanian, Michael J. Bowles, Nardev S. Khurmi, The American Journal of Cardiology ThrombosisCardiovascular DiseaseMedicineChronic Stable AnginaAntihypertensive Therapy	1982	75
Objective evaluation of three dose levels of diltiazem in patients with chronic stable angina V. Bala Subramanian, Nardev S. Khurmi, Michael J. Bowles, Journal of the American College of Cardiology Cardiovascular DiseaseDose LevelsChronic Stable AnginaAntihypertensive TherapyPharmacology	1983	68
Pulmonary Function in Patients With Acute Coronary Syndrome Treated With Ticagrelor or Clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] Pulmonary Function Substudy) Robert F. Storey, Richard C. Becker, Robert A. Harrington, The American Journal of Cardiology ThrombosisCardiovascular DiseaseBlood PlateletPulmonary FunctionHematology	2011	68

Page 1